Welcome to our dedicated page for Resmed SEC filings (Ticker: RSMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Resmed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Resmed's regulatory disclosures and financial reporting.
ResMed Inc. filed a current report describing its latest quarterly results and a new dividend declaration. The company issued a press release covering operations for the quarter ended December 31, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.
ResMed’s board declared a quarterly cash dividend of US $0.60 per share, with a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. dollars to NYSE common stockholders. Holders of CHESS Depositary Instruments on the ASX will receive the equivalent in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date is February 11, 2026 for both common stock and CDIs, and ResMed obtained an ASX waiver to defer conversions between its common stock and CDI registers from February 11–12, 2026.
ResMed Inc. director Peter C. Farrell reported a sale of company stock. On January 7, 2026, he sold 2,000 shares of ResMed common stock at a price of $248.83 per share. After this transaction, he beneficially owned 66,773 shares directly. The filing notes that the trade was conducted under a Rule 10b5-1 trading plan that was adopted on August 12, 2025, which is a pre-arranged plan that allows insiders to systematically sell shares over time.
ResMed Inc. director Peter C. Farrell reported a sale of company stock. On January 7, 2026, he sold 2,000 shares of ResMed common stock at a price of $248.83 per share. After this transaction, he beneficially owned 66,773 shares directly. The filing notes that the trade was conducted under a Rule 10b5-1 trading plan that was adopted on August 12, 2025, which is a pre-arranged plan that allows insiders to systematically sell shares over time.
ResMed Inc.'s Chairman and CEO Michael J. Farrell reported an options exercise and stock sale. On January 7, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of ResMed common shares. On the same day, he sold 4,991 ResMed common shares at a weighted average price of $248.4603 per share, in multiple trades between $246.801 and $249.969.
The transactions were conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Following these transactions, Farrell directly beneficially owned 466,223 ResMed common shares, held in his own name, and indirectly beneficially owned 2,090 shares through the Lisette and Michael Farrell Family Trust. He also held 49,912 ResMed common stock options after the reported exercise; these options first became exercisable on November 11, 2020 and vest one-third per year.
ResMed Inc.'s Chairman and CEO Michael J. Farrell reported an options exercise and stock sale. On January 7, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of ResMed common shares. On the same day, he sold 4,991 ResMed common shares at a weighted average price of $248.4603 per share, in multiple trades between $246.801 and $249.969.
The transactions were conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Following these transactions, Farrell directly beneficially owned 466,223 ResMed common shares, held in his own name, and indirectly beneficially owned 2,090 shares through the Lisette and Michael Farrell Family Trust. He also held 49,912 ResMed common stock options after the reported exercise; these options first became exercisable on November 11, 2020 and vest one-third per year.
RMD received a Rule 144 notice indicating that shareholder Peter C Farrell plans to sell 2,000 shares of common stock through Merrill Lynch on or about 01/07/2026 on the NYSE. The filing lists an aggregate market value of $497,580 for the planned sale and notes that 44,448,959 shares of the same class were outstanding.
The 2,000 shares to be sold were acquired on 11/11/2014 via a stock option from Peter C Farrell and paid for in cash. Over the past three months, Peter C Farrell previously sold 2,000 shares on 11/12/2025 for gross proceeds of $504,020 and another 2,000 shares on 12/04/2025 for $502,860. By signing the notice, the seller represents that he does not know of any material adverse information about the issuer’s operations that has not been publicly disclosed.
RMD received a Rule 144 notice indicating that shareholder Peter C Farrell plans to sell 2,000 shares of common stock through Merrill Lynch on or about 01/07/2026 on the NYSE. The filing lists an aggregate market value of $497,580 for the planned sale and notes that 44,448,959 shares of the same class were outstanding.
The 2,000 shares to be sold were acquired on 11/11/2014 via a stock option from Peter C Farrell and paid for in cash. Over the past three months, Peter C Farrell previously sold 2,000 shares on 11/12/2025 for gross proceeds of $504,020 and another 2,000 shares on 12/04/2025 for $502,860. By signing the notice, the seller represents that he does not know of any material adverse information about the issuer’s operations that has not been publicly disclosed.
Michael Farrell filed a notice to sell 4,991 shares of RMD common stock through Fidelity Brokerage Services LLC on January 7, 2026, with an aggregate market value of $1,240,065.29 on the NYSE.
The shares were acquired the same day via a cash exercise of a stock option originally granted on November 21, 2019. RMD has 145,966,294 common shares outstanding, and over the prior three months Farrell sold 8,009, 8,011, and 4,991 common shares in separate transactions, generating gross proceeds of $2,265,332.03, $2,000,772.95, and $1,254,795.79, respectively.
Michael Farrell filed a notice to sell 4,991 shares of RMD common stock through Fidelity Brokerage Services LLC on January 7, 2026, with an aggregate market value of $1,240,065.29 on the NYSE.
The shares were acquired the same day via a cash exercise of a stock option originally granted on November 21, 2019. RMD has 145,966,294 common shares outstanding, and over the prior three months Farrell sold 8,009, 8,011, and 4,991 common shares in separate transactions, generating gross proceeds of $2,265,332.03, $2,000,772.95, and $1,254,795.79, respectively.
ResMed Inc.'s Chief Financial Officer reported a small planned share sale. On 01/02/2026, the CFO sold 1,000 shares of ResMed common stock at a price of $241.75 per share in an open market transaction coded as a sale. The filing shows that after this transaction, the officer directly beneficially owns 86,495 shares of ResMed common stock.
The transaction was made under a Rule 10b5-1 trading plan that was adopted on February 19, 2025, indicating it was pre-arranged under SEC rules rather than a discretionary trade at the time of sale.
ResMed Inc.'s Chief Financial Officer reported a small planned share sale. On 01/02/2026, the CFO sold 1,000 shares of ResMed common stock at a price of $241.75 per share in an open market transaction coded as a sale. The filing shows that after this transaction, the officer directly beneficially owns 86,495 shares of ResMed common stock.
The transaction was made under a Rule 10b5-1 trading plan that was adopted on February 19, 2025, indicating it was pre-arranged under SEC rules rather than a discretionary trade at the time of sale.
ResMed Inc.'s Global General Counsel and Secretary reported a small stock sale in a Form 4 filing. On 01/02/2026, the officer sold 50 shares of ResMed common stock at a price of $241.75 per share. After this transaction, the officer beneficially owned 9,741 shares, held directly.
The filing notes that this transaction was conducted under a pre-established Rule 10b5-1 trading plan that was adopted on February 28, 2025. Such plans allow insiders to sell shares according to predetermined instructions, helping separate routine portfolio management from the timing of any company news.
ResMed Inc.'s Global General Counsel and Secretary reported a small stock sale in a Form 4 filing. On 01/02/2026, the officer sold 50 shares of ResMed common stock at a price of $241.75 per share. After this transaction, the officer beneficially owned 9,741 shares, held directly.
The filing notes that this transaction was conducted under a pre-established Rule 10b5-1 trading plan that was adopted on February 28, 2025. Such plans allow insiders to sell shares according to predetermined instructions, helping separate routine portfolio management from the timing of any company news.
RMD insider Brett Sandercock filed a notice of proposed sale of 1,000 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 241,750.00. The shares are listed on the NYSE, and the approximate sale date indicated is 01/02/2026, with 145,966,294 shares of common stock reported as outstanding.
The 1,000 shares to be sold were acquired on 11/11/2022 through restricted stock vesting from the issuer as compensation. In the past three months, Sandercock reported selling 3,000 common shares on 11/03/2025 for gross proceeds of 742,620.00 and 1,000 common shares on 12/01/2025 for gross proceeds of 244,160.00.
RMD insider Brett Sandercock filed a notice of proposed sale of 1,000 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 241,750.00. The shares are listed on the NYSE, and the approximate sale date indicated is 01/02/2026, with 145,966,294 shares of common stock reported as outstanding.
The 1,000 shares to be sold were acquired on 11/11/2022 through restricted stock vesting from the issuer as compensation. In the past three months, Sandercock reported selling 3,000 common shares on 11/03/2025 for gross proceeds of 742,620.00 and 1,000 common shares on 12/01/2025 for gross proceeds of 244,160.00.
ResMed (RMD) received a notice of proposed stock sales under Rule 144 from an insider. The filer plans to sell 50 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $12,087.50. These shares were acquired on 11/11/2023 through restricted stock vesting from the issuer as compensation. The notice also reports that the same person sold 50 shares of common stock on 12/01/2025 for gross proceeds of $12,208.00 over the past three months.
ResMed (RMD) received a notice of proposed stock sales under Rule 144 from an insider. The filer plans to sell 50 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $12,087.50. These shares were acquired on 11/11/2023 through restricted stock vesting from the issuer as compensation. The notice also reports that the same person sold 50 shares of common stock on 12/01/2025 for gross proceeds of $12,208.00 over the past three months.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and share sale. On 12/08/2025, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, converting them into the same number of common shares.
On the same date, he sold 4,991 ResMed common shares at a weighted average price of $251.4117 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed shares, held 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, and beneficially owned 54,903 stock options with underlying ResMed shares.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and share sale. On 12/08/2025, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, converting them into the same number of common shares.
On the same date, he sold 4,991 ResMed common shares at a weighted average price of $251.4117 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed shares, held 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, and beneficially owned 54,903 stock options with underlying ResMed shares.